HRD and Resistance to PAPPi in EOC Patients

Lei Li

Status: Enrolling

Conditions: Poly(ADP-ribose) Polymerase Inhibitor; Epithelial Ovarian Cancer; Homologous Recombination Deficiency; Drug Resistance; Overall Survival; Progression-free Survival; Homologous Recombination Repair Gene Mutation

Treatments: Genetic: Testing of homologous recombination deficiency

Study type: Observational

Funder types: Other

Identifiers

NCT05310370

EOC-HRD3

Details and patient eligibility

About

The association between homologous recombination (HR) gene mutations and homologous recombination deficiency (HRD) status in Chinese epithelial ovarian cancer (EOC) patients has been investigated in previous studies (NCT04190667 and NCT04651920). This study is to investigate the correlation between HRD and the resistance to poly(ADP-ribose) polymerase inhibitors (PARPi) in a Chinese cohort confirmed of epithelial ovarian cancer. The mutated genes, HRD score model and their relationship with the prognosis is the primary endpoint in this study. All enrolled patients will accept PARPi as maintenance therapy after the complete or partial remission of targeted lesions. A multiple panel testing of germline and somatic genes, including BRCA1/2, and HRD score are provided for all participants.

Enrollment: 400 estimated patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Aged 18 years or older
• Pathological confirmation of epithelial ovarian cancer
• With available tumor tissues
• Given consents to participate the study
• With detailed follow-up outcomes

Exclusion criteria

• Not meeting all of the inclusion criteria
• Declining to accept PARPi as maintenance therapy after the major treatment for cancer